Leflunomide: Long-term clinical experience and new uses

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 5, 2005, Pages 787-801

  Kaltwasser, J Peter ^a   Behrens, Frank ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Clinical trials; Combination therapy; Efficacy; Leflunomide; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Safety

Indexed keywords

CIMETIDINE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PYRIMIDINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; TOLBUTAMIDE; WARFARIN;

ANEMIA; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATING DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG DISEASE; LYMPHOMA; NAUSEA; NONHUMAN; PANCYTOPENIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PSORIATIC ARTHRITIS; PYRIMIDINE SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; VASCULITIS; WEGENER GRANULOMATOSIS; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; ISOXAZOLES;

EID: 19044396459     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.5.787     Document Type: Review

References (90)

1. WOOLF AD, PFLEGER B: Burden of major musculoskeletal conditions. Bull. World Health Organ. (2003) 81(9):646-656.
2. FRIES JF, WILLIAMS CA, MORFELD D, SINGH G, SIBLEY J: Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. (1996) 39(4):616-622.
3. WILES NJ, LUNT M, BARRETT EM et al.: Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. (2001) 44(5):1033-1042.
4. JOBANPUTRA P, WILSON J, DOUGLAS K, BURLS A: A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (2004) 43 (2):206-210.
5. SOKKA T, PINCUS T: Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J. Rheumatol. (2002) 29(12):2521-2524.
6. WOLFE F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin. Rheumatol. (1995) 9(4):619-631.
7. FLEISCHMANN RM, IQBAL I, STERN RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin. Drug Saf. (2004) 3(5):391-403.
8. American College of Rheumatology Hotline: FDA Meeting March 2003: Update on the Safety of New Drugs for Rheumatoid Arthritis. Part II: CHE Infection and other Safety Issues (2003).
9. JONES G, CROTTY M, BROOKS P. Interventions for psoriatic arthritis (Cochrane review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2001.
10. BARTLETT RR, BRENDEL S, ZIELINSKI T, SCHORLEMMER HU: Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant. Proc. (1996) 28(6):3074-3078.
11. FOX RI, HERRMANN ML, FRANGOU CG, WAHL GM, MORRIS RE, KIRSCHBAUM BJ: How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs (1999) 12(4):301-315.
12. CHERWINSKI HM, COHN RG, CHEUNG P et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pytimidine biosynthesis. J. Pharmacol. Exp. Ther. (1995) 275(2):1043-1049.
13. GREENE S, WATANABE K, BRAATZ-TRULSON J, LOU L: Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. (1995) 50(6):861-867.
14. WILLIAMSON RA, YEA CM, ROBSON PA et al.: Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. (1995) 270(38):22467-22472.
15. RÜCKEMANN K, FAIRBANKS LD, CARREY EA et al.: Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. (1998) 273(34):21682-21691.
16. CUTOLO M, SULLI A, GHIORZO P, PIZZORNI C, CRAVIOTTO C, VILLAGIO B: Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(4):297-302.
17. SIEMASKO KF, CHONG AS, WILLIAMS JW, BREMER EG, FINNEGAN A: Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation (1996) 61:635-642.
18. URUSHIBARA M, TAKAYANAGI H, KOGA T et al.: The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. (2004) 50(3):794-804.
19. ROZMAN B: Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet. (2002) 41(6): 421-430.
20. PRAKASH A, JARVIS B: Leflunomide: a review of its use in active rheumatoid arthritis. Drugs (1999) 58(6):1137-1164.
21. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. (1999) 42(7):1322-1328.
22. OSIRI M, SHEA B, ROBINSON V et al.: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol. (2003) 30(6):1182-1190.
23. SMOLEN JS, EMERY P, KALDEN JR et al.: The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic therapy. J. Rheumatol. (2004) 71(Suppl.):13-20.
24. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. (1999) 159(21):2542-2550.
25. SIVA C, EISEN SA, SHEPHERED R et al.: Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum. (2003) 49(6):745-751.
26. VAN RIEL PL, SMOLEN JS, EMERY P et al.: Leflunomide: a manageable safety profile. J. Rheumatol. (2004) 71(Suppl.):21-24.
27. FIEHN C, ROCHEL E, HO AD, MAX R: Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEE Ann. Rheum. Dis. (2004) 63(6):746-747.
28. POOR G, STRAND V: Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (2004) 43(6):744-749.
29. MLADENOVIC V, DOMLJAN Z, ROZMAN B et al.: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled. Phase II study. Arthritis Rheum. (1995) 38(11):1595-1603.
30. CANNON GW, KREMER JM: Leflunomide. Rheum. Dis. Clin. North Am. (2004) 30(2):295-309.
31. MICELI-RICHARD C, DOUGADOS M: Leflunomide for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. (2003) 4(6):987-997.
32. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 353(9149):259-266.
33. KALDEN JR, SCOTT DL, SMOLEN JS et al.: Improved functional ability in patients with rheumatoid arthritis-longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J. Rheumatol. (2001) 28(9):1983-1991.
34. SCOTT DL, SMOLEN JS, KALDEN JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. (2001) 60(10):913-923.
35. STRAND V, TUGWELL P, BOMBARDIER C et al.: Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. (1999) 42(9):1870-1878.
36. COHEN S, CANNON GW, SCHIFF M et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. (2001) 44(9):1984-1992.
37. EMERYE BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexare for the treatment of rheumatoid arthritis. Rheumatology (2000) 39(6):655-665.
38. SCOTT DL, STRAND V: The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology (2002) 41(8):899-909.
39. REECE RJ, KRAAN MC, RADJENOVIC A et al.: Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum. (2002) 46(2):366-372.
40. SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized clinical trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigator's Group. Arthritis Rheum. (2000) 43(3):495-505.
41. LARSEN A, KVIEN TK, SCHATTENKIRCHNER M et al.: Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand. J. Rheumatol. (2001) 30(3):135-142.
42. VAN DER HEIJDE D, KALDEN J, SCOTT D, SMOLEN J, STRAND V: Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann. Rheum. Dis. (2004) 63(6):737-739.
43. KALDEN JR, SCHATTENKIRCHNER M, SORENSEN H et al.: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum. (2003) 48(6):1513-1520.
44. KALDEN JR, SMOLEN JS, EMERY P et al.: Leflunomide in combination therapy. J. Rheumatol. (2004) 71(Suppl.):25-30.
45. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2002) 137(9):726-733.
46. KREMER JM, GENOVESE MC, CANNON GW et al.: Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J. Rheumatol. (2004) 31(8):1521-1531.
47. CHUNG C, MALLON C, SPADY B, RUSSELL AS, MAKSYMOWYCH WP: Survival analysis of treatment with leflunomide, combination leflunomide/methotrexate, and infliximab for rheumatoid arthritis in routine clinical practice. Presented at The 68th Annual Meeting of the American College of Rheumatology (2003): Abstract 793.
48. TA KT, CARTWRIGHT V, MICHAUD K, WOLFE F: Safety data comparing combination therapy of leflunomide plus methotrexate to leflunomide alone: a five-year prospective study. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 288.
49. DOUGADOS M, EMERY P, LEMMEL EM, ZERBINI CAF, BRIN S, VAN RIEL P: When a DMARD fails, should patients switch to sulfasalzine or add sulfasalazine to continuing leflunomide? Ann. Rheum. Dis. (2005) 65:44-51.
50. GODINHO F, GODFRIN B, EL MAHOU S, NAVAUX F, ZABRANIECKI L, CANTAGREL A: Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. (2004) 22(3):328-330.
51. HANSEN KE, CUSH J, SINGHAL A et al.: The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. (2004) 51(2):228-232.
52. PERDRIGER A, COMBE B, KUNTZ JJ et al.: A French multicenter retrospective study on the efficacy and safety of infliximab in association with DMARDs other than methotrexate. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract SAT0356.
53. FLENDRIE M, CREEMERS MC, WELSING PM, VAN RIEL PL: The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis: a longitudinal observational study. Rheumatology (2004) [Epub ahead of print].
54. ANTONI C, NÜSSLEIN HG, WOLLENHAUPT J, BURMESTER GR, KROGER K, KALDEN JR: Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract FRI0093.
55. STRUPPLER CI, THIES W, SCHATTENKIRCHNER M, KELLNER H: Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) patients. Presented at The Annual European Congress of Rheumatology EULAR 2002 (2002): Abstract AB0157.
56. KIELY PDW, JOHNSON DM: Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (2002) 41(6):631-637.
57. MARIETTE X, BIJLSMA JWJ, HEROLD M, EISELSTEIN J, SPENCER-GREEN GT, KUPPER H: Efficacy evaluation of adalimumab (Humira®) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract FRI0099.
58. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. (2003) 30(12):2563-2571.
59. TESSER J, FELSICHMANN R, DORE R et al.: Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol. (2004) 31(4):649-654.
60. TASSIULAS I, DUNCAN SR, CENTOLA M, THEOFILOPOULOS AN, BOUMPAS DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis.. Hum. Immunol. (1999) 60(6):479-491.
61. LIANG GC, BARR WG: Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J. Clin. Rheumatol. (2001) 7(6):366-370.
62. REICH K, HUMMEL KM, BECKMANN I, MOSSNER R, NEUMANN C: Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br. J. Dermatol. (2002) 146(2):335-336.
63. TLACUILO-PARRA JA, GUEVARA-GUTIERREZ E, RODRIGUEZ-CATELLANOS MA, ORNELAS-AGUIRRE JM, BARBRA-GOMEZ JF, SALAZAR-PARAMO M: Leflunomide in the treatment of psoriasis: results of a Phase II open trial. Br. J. Dermatol. (2004) 150(5):970-976.
64. THAMI G, GARG G: Leflunomide in psoriasis and psoriatic arthritis: a preliminary study. Arch. Dermatol. (2004) 140(10):1288-1289.
65. KALTWASSER JP, NASH P, GLADMAN D et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. (2004) 50(6):1939-1950.
66. CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum. (1996) 39(12):2013-2020.
67. SILVERMAN E, SPIEGEL L, JUNG LK et al.: Efficacy and safety of leflunomide (LEF) versus methotrexate (MTX) in the treatment of pediatric patients with juvenile rheumatoid arthritis (JRA). Presented at The 68th Annual Meeting of the American College of Rheumatology (2003): Poster 511.
68. SILVERMAN E, MOUY R, SPIEGEL L et al.: Durability of efficacy, safety, and tolerability of leflunomide (LEF) or methotrexate (MTX) over 48 weeks of treatment in pediatric patients with juvenile rheumatoid arthritis (JRA). Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 72.
69. HAIBEL H, RUDWALEIT M, BRAUN J, SIEPER J. Six months open label trial of leflunomide in ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(1):124-126.
70. VAN DENDEREN JC, VAN DER PAARDT M, NURMOHAMED MT, DE RYCK YM, DIJKMANS BAC, VAN DER HORST-BRUINSMA IE: Double-blind, randomized, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract SAT0033.
71. METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener s granulomatosis. Rheumatology (2004) 43(3):315-320.
72. REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10(7):480-483.
73. TAM L-S, LI EK, WONG C-K, LAM CW, SZETO C-C: Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus (2004) 13(8):601-604.
74. PRAJAPATI DN, KNOX JF, EMMONS J, SAEIAN K, CSUKA ME, BINION DG: Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J. Clin. Gastroenterol. (2003) 37(2):125-128.
75. SCAGLIUSI P, D'AMORE M, SCAGLIUSI A, MINENNA G: Le nuove terapie nella syndrome di Sjögren: efficacia della leflunomide. Reumatismo. (2004) 56(3 Suppl. 3):271 (Abstract P04).
76. BENUCCI M, LI GOBBI F, PIERFEDERICI P: Modificazioni dei parametric della scintigrafia delle ghiandole salivary in corso di terapia con leflunomide in pazienti con syndrome di Sjögren. Reumatismo (2004) 56(3; Suppl. 3):324 (Abstract P112).
77. SCHADLICH PK, ZEIDLER H, ZINK A et al.: Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany. Z. Rheumatol. (2004) 63(1):59-75.
78. OLLENDORF DA, PETERSON AN, DOYLE J, HUSE DM: Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am. J. Manag. Care (2002) 8(7 Suppl.):S203-S213.
79. CANNON GW, STRAND V, OED C, SCARAZZINI L, HOLDEN WL: Adverse events during clinical trials comparing leflunomide, methotrexate, sulfasalazine and placebo. Meta-analysis of data from Phase II and III controlled clinical trials. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract and poster FRI0014.
80. UJFALUSSY I, KOO E, SESZTAK M, GERGELY P: Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z. Rheumatol. (2003) 62(2):155-160.
81. WHITING-O'KEEFE QE, FYE KH, SACK KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. (1991) 90(6):711-716.
82. CANNON GW, HOLDEN WL, JUHAERI J, DAI W, SCARAZZINI L, STANG P: Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J. Rheumatol. (2004) 31(10):1906-1911.
83. CANNON GW, STRAND V, SCARAZZINI L, HOLDEN WL: Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate between September 1998 and June 2003. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 291.
84. VAN ROON EN, JANSEN TL, HOUTMAN NM, SPOELSTRA P, BROUWERS JR: Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. (2004) 27(5):345-352.
85. SUISSA S, ERNST P, HUDSON M, BITTON A, KEZOUH A: Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am. J. Med. (2004) 117(2):87-92.
86. American College of Rheumatology Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis part III: safety and efficacy update on leflunomide (Arava® 2003).
87. CANNON GW, STRAND V, SIMON LS et al.: Interstitial lung disease in rheumatoid arthritis patients receiving leflunomide. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 292.
88. ITO S, SUMIDA T. Interstitial lung disease associated with leflunomide. Intern. Med. (2004) 43(12):1103-1104.
89. BRENT RL: Teratogen update: reproductive risks of leflunomide (Arava™): a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology (2001) 63(2):106-112.
90. CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease-modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J. Rheumatol. (2003) 30(2):241-246.